This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...
Cosentyx (secukinumab) comes as a subcutaneous injection under the skin or an intravenous (IV) infusion into a vein. Doctors may prescribe it to treat plaque psoriasis, psoriatic arthritis, and other ...
UVA implementation data showed injection-related reactions needing active management in 0.5% of subcutaneous administrations versus 37% with intravenous dosing, contributing $100.27 lower per-visit ...
September 16, 2026. A new subcutaneous injection formulation for the Alzheimer's disease drug "Leqembi," "Leqembi Subcutaneous Injection 250mg Pen," has been approved. The generic name is the same as ...
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors. On Dec. 27, 2024, the Food and Drug ...
Verywell Health on MSN
IV vs. subcutaneous cancer therapies: What’s the difference?
Medically reviewed by Marla Anderson, MD Key Takeaways IV therapy delivers cancer medicine directly into a vein and often requires a longer infusion visit at a clinic or hospital.Subcutaneous therapy ...
Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...
Keytruda Qlex, a subcutaneous formulation, is FDA-approved for solid tumors in patients 12 and older, offering an alternative to intravenous administration. Study MK-3475A-D77 showed comparable ...
Merck (MRK) has secured Japanese regulatory approval for KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous injection, covering all indications currently approved for ...
Hello! I'm Newt, a hospital pharmacist!On September 16, 2026, a new drug that I am personally very interested in was approved.Its name is Keyject® Subcutaneous Injection.The generic name is ...
– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results